Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Retour aux sources: defining the structural basis of glutamate receptor activation.

Dawe GB, Aurousseau MR, Daniels BA, Bowie D.

J Physiol. 2015 Jan 1;593(1):97-110. doi: 10.1113/jphysiol.2014.277921. Epub 2014 Oct 21. Review.

2.

Trafficking of kainate receptors.

Pahl S, Tapken D, Haering SC, Hollmann M.

Membranes (Basel). 2014 Aug 20;4(3):565-95. doi: 10.3390/membranes4030565. Review.

3.

NMDA receptor structures reveal subunit arrangement and pore architecture.

Lee CH, Lü W, Michel JC, Goehring A, Du J, Song X, Gouaux E.

Nature. 2014 Jul 10;511(7508):191-7. doi: 10.1038/nature13548. Epub 2014 Jun 22.

4.

Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis.

Fritsch B, Reis J, Gasior M, Kaminski RM, Rogawski MA.

J Neurosci. 2014 Apr 23;34(17):5765-75. doi: 10.1523/JNEUROSCI.5307-13.2014.

5.

Forced arm use is superior to voluntary training for motor recovery and brain plasticity after cortical ischemia in rats.

Schneider A, Rogalewski A, Wafzig O, Kirsch F, Gretz N, Krüger C, Diederich K, Pitzer C, Laage R, Plaas C, Vogt G, Minnerup J, Schäbitz WR.

Exp Transl Stroke Med. 2014 Feb 14;6(1):3. doi: 10.1186/2040-7378-6-3.

6.

Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Rubio MD, Drummond JB, Meador-Woodruff JH.

Biomol Ther (Seoul). 2012 Jan;20(1):1-18. doi: 10.4062/biomolther.2012.20.1.001. Review.

7.

Neto2 interacts with the scaffolding protein GRIP and regulates synaptic abundance of kainate receptors.

Tang M, Ivakine E, Mahadevan V, Salter MW, McInnes RR.

PLoS One. 2012;7(12):e51433. doi: 10.1371/journal.pone.0051433. Epub 2012 Dec 6.

8.

Kainate receptor signaling in pain pathways.

Bhangoo SK, Swanson GT.

Mol Pharmacol. 2013 Feb;83(2):307-15. doi: 10.1124/mol.112.081398. Epub 2012 Oct 24. Review.

9.

NFIX regulates neural progenitor cell differentiation during hippocampal morphogenesis.

Heng YH, McLeay RC, Harvey TJ, Smith AG, Barry G, Cato K, Plachez C, Little E, Mason S, Dixon C, Gronostajski RM, Bailey TL, Richards LJ, Piper M.

Cereb Cortex. 2014 Jan;24(1):261-79. doi: 10.1093/cercor/bhs307. Epub 2012 Oct 4.

10.

Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors.

Aroniadou-Anderjaska V, Pidoplichko VI, Figueiredo TH, Almeida-Suhett CP, Prager EM, Braga MF.

Neuroscience. 2012 Sep 27;221:157-69. doi: 10.1016/j.neuroscience.2012.07.006. Epub 2012 Jul 13.

11.

Channel-opening kinetic mechanism of wild-type GluK1 kainate receptors and a C-terminal mutant.

Han Y, Wang C, Park JS, Niu L.

Biochemistry. 2012 Jan 24;51(3):761-8. doi: 10.1021/bi201446z. Epub 2012 Jan 9.

12.

Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.

Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE.

J Med Chem. 2012 Jan 12;55(1):327-41. doi: 10.1021/jm201230z. Epub 2011 Dec 14.

13.

Editing of neurotransmitter receptor and ion channel RNAs in the nervous system.

Hood JL, Emeson RB.

Curr Top Microbiol Immunol. 2012;353:61-90. doi: 10.1007/82_2011_157. Review.

14.

BTB-Kelch proteins and ubiquitination of kainate receptors.

Marshall J, Blair LA, Singer JD.

Adv Exp Med Biol. 2011;717:115-25. doi: 10.1007/978-1-4419-9557-5_10. Review.

15.

Control of GABA Release at Mossy Fiber-CA3 Connections in the Developing Hippocampus.

Safiulina VF, Caiati MD, Sivakumaran S, Bisson G, Migliore M, Cherubini E.

Front Synaptic Neurosci. 2010 Feb 22;2:1. doi: 10.3389/neuro.19.001.2010. eCollection 2010.

16.

Kainate receptors coming of age: milestones of two decades of research.

Contractor A, Mulle C, Swanson GT.

Trends Neurosci. 2011 Mar;34(3):154-63. doi: 10.1016/j.tins.2010.12.002. Epub 2011 Jan 20. Review.

17.

The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.

Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF.

J Pharmacol Exp Ther. 2011 Feb;336(2):303-12. doi: 10.1124/jpet.110.171835. Epub 2010 Oct 20.

18.

Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310.

Atlason PT, Scholefield CL, Eaves RJ, Mayo-Martin MB, Jane DE, Molnár E.

Mol Pharmacol. 2010 Dec;78(6):1036-45. doi: 10.1124/mol.110.067934. Epub 2010 Sep 13.

19.

Spinal mediators that may contribute selectively to antinociceptive tolerance but not other effects of morphine as revealed by deletion of GluR5.

Gregus AM, Inra CN, Giordano TP 3rd, Costa AC, Rajadhyaksha AM, Inturrisi CE.

Neuroscience. 2010 Aug 11;169(1):475-87. doi: 10.1016/j.neuroscience.2010.03.051. Epub 2010 Mar 29.

20.

Deletion of the GluR5 subunit of kainate receptors affects cocaine sensitivity and preference.

Gregus AM, Tropea TF, Wang Y, Hauck SC, Costa AC, Rajadhyaksha AM, Inturrisi CE.

Neurosci Lett. 2010 Jan 14;468(3):186-9. doi: 10.1016/j.neulet.2009.10.071. Epub 2009 Oct 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk